CD19 and neoplasm: Moreover, the nanobody‐based CD19 CAR‐T, CD20 CAR‐T and bispecific CAR‐T cells demonstrated high potential to kill Burkitt lymphoma tumor cells and patient‐derived tumor cells in vitro, further confirming the effectiveness of nanobody‐based CAR‐T cell therapy [135].